A Wake Forest piece looks at GLP-1 medicines through the lens of brain research on motivation and reward.
Recap by typeshit. Post by Facebook on Facebook.
Lilly's pill had major heart events in 4.2% of patients vs 5.0% on insulin glargine. The Clinical Trial Vanguard argues rivals now need to show benefit, not just safety.
A Future Health & Medical Innovation panel weighs how much of the growing interest in peptides and exosomes is backed by evidence.
The aging doctor shares a headline saying new studies point to GLP-1 drugs slowing the biological clock, and notes himself that more research is needed.
An explainer on how GLP-1 drugs act on reward and craving in the brain, and the research testing them against alcohol, nicotine and other substance use.
PharmExec says incretin drugs showed up across heart failure, kidney disease, AF and prevention sessions, framed as heart therapies rather than just weight drugs.
Pooling six trials with 3,459 adults, researchers saw bigger drops in weight, HbA1c and blood pressure at the higher dose. They flag small liver enzyme rises to monitor.
Loading…